Outcomes of Elderly Patients with Mantle Cell Lymphoma
Author Information
Author(s): Pahnke Simon, Abalo Kossi D., Ekberg Sara, Albertsson-Lindblad Alexandra, E. Smedby Karin, Jerkeman Mats, Glimelius Ingrid
Primary Institution: Uppsala University
Hypothesis
More detailed knowledge about the oldest MCL patients is needed.
Conclusion
The majority of MCL patients aged 80 years or older receive and respond to primary treatment, but their median overall survival is significantly shorter than that of a matched healthy population.
Supporting Evidence
- Patients aged 80 or older had a median overall survival of 1.5 years compared to 5.1 years for matched comparators.
- 82% of patients received active oncological treatment.
- More than 80% of patients responded to first-line treatment.
Takeaway
This study looked at older patients with a type of blood cancer called mantle cell lymphoma. It found that while many of them can get treatment, they often don't live as long as healthy people their age.
Methodology
The study used the Swedish Lymphoma Register and other population-based registers to estimate progression-free survival and overall survival for MCL patients aged 80 or older.
Potential Biases
Imbalances in patient and disease characteristics between groups treated with different regimens may introduce bias.
Limitations
The observational nature of the data limits the ability to compare outcomes between different treatment regimens and lacks data on chemotherapy regimen dose modifications.
Participant Demographics
The majority of patients were male (67%), with 60% aged 80-84, 31% aged 85-89, and 9% over 90 years.
Statistical Information
Confidence Interval
95% CI 1.2–1.9
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website